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Background: A cost-effectiveness evaluation comparing home-based and hospital-based treatment with intravenous antibiotics for
respiratory exacerbations in adults with cystic fibrosis (CF) has not been previously undertaken.
Methods: The study was conducted in a UK adult CF centre from a health service perspective. Clinical outcome and resource use data were
obtained from a retrospective one-year study and combined with unit cost data in an incremental economic analysis. The primary outcome
measure was percentage change in FEV1; ‘‘effectiveness’’ was defined as maintenance of baseline average FEV1 over the one-year study period.
Results: 116 patients received 454 courses of intravenous antibiotics. At the end of 1 year, there had been a mean percentage decline in
FEV1 compared with baseline average for home-treated patients but an improvement for hospital-treated patients (Tukey’s HSD mean
difference 10.1%, 95% CI 2.9 to 17.2, p =0.003). Treatment was deemed ‘‘effective’’ in more hospital (58.8%) than home (42.6%) patients.
The cost of hospital treatment was higher than home treatment (mean difference U9005, 95% CI 3507 to 14,700, p <0.001). The mean ICER
was U46,098 (2.5th and 97.5th percentiles 374,044 and 362,472).
Conclusions: Hospital treatment was more effective but more expensive than home treatment. Potential methods to improve outcome at
home should be considered but these may have resource implications.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cost-effectiveness; Respiratory infection; Home therapy; Cystic fibrosis1. Introduction
In the United Kingdom, 28 million working days are
lost because of respiratory illness every year and the
respiratory death rate is twice the European average, at 105
per 100,000 people [1]. Data from 196 patients attending
the Manchester CF Unit showed that in 2003, 113 patients
were attending work or school but 1799 days were lost
because of sickness. Despite this, respiratory disease is not
prioritised like heart disease or cancer and has no National
Service Framework. Effective management of chronic lung
disease would reduce the huge burden it places on the1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.08.003
* Corresponding author. Tel.: +44 161 275 7146; fax: +44 161 275 5043.
E-mail address: judith.thornton@manchester.ac.uk (J. Thornton).National Health Service and patients, but needs to be
evidence-based, better resourced and supported by Govern-
ment policy. The resultant lack of standardised approaches
to care or policy-driven initiatives mean that resources are
not directed strategically to respiratory programmes and not
all patients are treated optimally. This is apparent in
treatment of infective episodes in adults with cystic fibrosis
(CF) where patient outcome is influenced by the approach
to, and site of, care [2].
Adults with CF experience repeated infective respiratory
exacerbations leading to continued decline in lung function
[3]. Eventually, death results from respiratory failure [4].
Standard treatment for exacerbations is intravenous anti-
biotics, which may be administered in hospital or at home.
Home treatment is well established in the UK [5], because of
both the lack of inpatient beds and patient preference. The4 (2005) 239 – 247ed by Elsevier B.V. All rights reserved.
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infection, less time off work or school, improved quality of
life, and reduced costs for the healthcare provider [6].
We have examined the clinical outcome of patients
receiving intravenous antibiotics [7]. There were greater
improvements in lung function and nutrition among hospital-
treated patients compared with home-treated patients; these
differences in outcome were apparent after one course of
intravenous antibiotics and were maintained after one year of
treatment. However, it could be expected that treatment in
hospital would result in higher costs to the health service
because of, for example, the cost of hospital accommodation.
Would the improved outcome after hospital treatment justify
the increased costs that are required compared with home
treatment? Therefore, the aim of this study was to compare
the cost-effectiveness of home and hospital treatment with
intravenous antibiotics over both one course and one year of
treatment in adults with CF.2. Patients and methods
2.1. Study design
The retrospective, observational, one-year pragmatic
study was conducted in the Manchester Adult CF Centre, a
specialist centre which treats approximately 220 adults with
CF per year. Ethics approval was obtained and patients were
informed of the study. The study recruited all adult patients
(16 years) with confirmed CF who experienced at least one
respiratory exacerbation (defined as an increase in lower
respiratory tract symptoms requiring treatment with intra-
venous antibiotics) during the one-year study. Patients were
excluded if they received intravenous antibiotics for con-
ditions other than respiratory infections or if they received
treatment at other hospitals (shared care).
2.2. Allocation to treatment groups
The study was analysed on an intention-to-treat basis. The
site of home or hospital treatment for each individual course
of treatment had been decided prospectively after discussion
between the treating physician (AKW) and the patient. This
was based on the severity of the presenting clinical
symptoms and the competency of the patient to administer
intravenous antibiotics but was ultimately the choice of the
patient. In the study, courses of intravenous antibiotics were
categorised retrospectively by an independent investigator
(JT) according to where treatment had been started (regard-
less of any changes partway through the course). Thus,
courses where treatment had been started at home were
defined as home courses and courses where treatment started
in hospital were defined as hospital courses. Patients were
then allocated retrospectively to treatment groups according
to where they received most treatment over one year.
Although some patients had received all their treatmenteither at home or in hospital, other patients received almost
equal amounts of home and hospital treatment over the one-
year study period. Therefore, a pragmatic method of
categorisation was used: ‘‘home’’ patients were those in
whom the intention had been to treat at home in >60% of
courses and who, therefore, had received most of their
treatment at home; ‘‘hospital’’ patients were those in whom
the intention had been to treat in hospital in >60% of courses
and who, therefore, had received most of their treatment in
hospital; and ‘‘both’’ patients were those in whom the
intention had been to treat in hospital or at home in 40–60%
of courses and thus who had received almost equal amounts
of home and hospital treatment.
2.3. Outcome
The primary clinical outcome variable was forced
expiratory volume in 1 s (FEV1). For home treatment,
spirometric testing was performed at the start and end of
each course of intravenous antibiotics. In hospital, spiromet-
ric testing was performed at admission, twice weekly, and at
discharge. Two baseline FEV1 values were established in
each patient for the one-year baseline period which preceded
the one-year study period. The ‘‘best’’ FEV1 was the highest
FEV1 during the baseline year and the ‘‘average’’ FEV1 was
the mean of all FEV1 values recorded during that period. The
percentage of predicted FEV1 for a healthy subject of the
same age, height and sex was calculated for both values [8].
2.3.1. Clinical effectiveness of treatment courses
FEV1 was recorded for the start and end of each course of
antibiotics. The outcome after a single course of treatment
was a comparison with baseline ‘‘best’’ FEV1 and, for each
course, the percentage change from baseline ‘‘best’’ to the end
of the course was calculated. For the economic evaluation, a
definition of effectiveness of treatment was needed. In
practice, the main aim of treatment with antibiotics is to
achieve and maintain the patient’s best lung function.
Therefore, a course of treatment was defined as ‘‘effective’’
if lung function was maintained at baseline ‘‘best’’, that is, the
percentage decline in FEV1 was 0%.
2.3.2. Clinical effectiveness over one-year study period
For the one-year study period, the final FEV1 was
recorded as the last value of the last course at the end of
this period. Over time, however, the mean baseline value may
more accurately represent the patient’s everyday condition.
Therefore, the outcome after 1 year was a comparison with
baseline ‘‘average’’ FEV1 (percentage change in FEV1 from
baseline ‘‘average’’ to final). For the economic evaluation,
treatment over the study period was defined as ‘‘effective’’ if
lung function was maintained at baseline ‘‘average’’, that is,
the percentage decline in FEV1 was0%. However, because
the natural history of CF is characterised by a continued
decline in lung function, this requirement for no decline from
baseline lung function over 1 year may be unrealistic [3].
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definition of effectiveness: 2% decline in FEV1.
2.4. Cost of treatment
The study was conducted from the perspective of the
secondary care provider (NHS trust). The costing method-
ology has been described in detail elsewhere [9]. All
healthcare resource use associated with infection manage-
ment was collected for every patient over the one-year study
period (Table 1). The costs were calculated as resource use
multiplied by the unit cost of the resource. The unit costs were
obtained from the NHS Trust, including the specific CF Unit
budget, the British National Formulary and the hospital
supplies catalogue. All costs were calculated for the year
2002 and reported in UK sterling.
The use and costs of i.v. antibiotics, disposable equip-
ment and use of home kits were estimated, together with the
cost of sputum microbiology and sensitivity and blood drug
level assays.
To determine the cost of clinic appointments, the time
spent with one patient per appointment was estimated
through observation using a time sheet completed by each
member of staff attending the patient. Nursing, medical,
physiotherapy and other staff costs were then obtained from
the CF Unit budget and the cost of staff time estimated. The
number of days in hospital related to i.v. antibiotic treatment
for study patients was obtained from clinical records. Staff
costs were obtained from the CFUnit budget and allocated on
a Fcost per day_ basis. A standard time was derived for home
visits by CF nurses through interview and the cost estimated
from staff costs in the CF budget. The number of home visits
by staff was collected from the clinical records. The time
taken for a home visit was determined by interviewing staff
and salary cost calculated from the CF unit budget. An
estimate of the travelling time from the clinic to each patient’s
home was obtained from the Automobile Association. The
hospital pay-roll department provided the mileage allowance
payable for home visits and the cost of travel was calculated.Table 1
Summary of resource use parameters collected in this study
Data category Parameters
Resource use Variable resource use: intravenous
antibiotics; sputum microbiology;
blood drug level assays; standard home kits.
Staff resource use: clinic appointment;
inpatient day; home visit
Fixed resource use: clinic appointment;
inpatient day; home visit
Unit costs Variable unit costs: drug and disposables costs
microbiology, home kits
Staff unit costs: standard costs for staff emplo
in clinics, hospital ward and home visits
Fixed unit costs: maintaining a ward and a CFFixed resource use was included in the study. The NHS
Trust’s finance department provided information on the
components and allocation of fixed costs for the ward and
outpatient clinic to the CF budget. These were then used to
estimate the fixed cost per hour related to an inpatient stay or a
clinic attendance.
2.5. Other resources
The resources used and informal support required by the
patient and their family during home and hospital treatment
were determined via a postal self-completion questionnaire.
Patients were asked to report the following information
within 1 month of their most recent infection episode: mode
of transport to hospital, time spent preparing and administer-
ing injections, phone calls to/from clinic, visits from CF or
community nurses, help from family or friends in preparing
and administering home treatment, and time off work/
college/school (for both patient and care-giver).
2.6. Statistical analysis
SPSS (version 11.5) was used to compare changes in lung
function between treatment courses (independent samples t-
tests) and between treatment groups (analysis of variance,
ANOVA). Differences in effectiveness were compared using
Chi-square test.
The distribution of cost data is typically truncated and
positively skewed. This is caused by both the presence of a
relatively small number of patients with a high cost of
treatment and the absence of negative costs [10,11]. Thus,
standard parametric statistical tests are inappropriate. How-
ever, standard non-parametric tests do not compare arithmetic
means, the measure of interest for decision makers. There-
fore, non-parametric bootstrapping, which involves simula-
tion of data through repeated sampling of the study data set
(1000 iterations with Excel), was used to calculate confidence
intervals and make statistical inferences about the arithmetic
means. This allowed comparison of the total costs ofSource
In situ data collection (clinical records)
In situ data collection, (clinic and ward diaries,
clinical records, time and motion study)
In situ data collection, (clinic and ward diaries,
clinical records, time and motion study)
, BNF; Pharmacy and Supplies departments;
Microbiology and Pathology departments
yed Finance department (CF unit budget)
clinic Finance department (CF unit budget)
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bootstrapped data.
If the difference in effectiveness was not statistically
significant, a cost-minimisation analysis was planned, con-
sidering only the difference in cost between the two settings.
If there was a statistically significant difference in effective-
ness between home and hospital treatment, a cost-effective-
ness analysis (with calculation of incremental cost-
effectiveness ratios, ICER) was planned. The ICER is the
ratio of the differences in cost to the differences in
effectiveness between the two settings thus expresses the
cost required to achieve each additional unit of outcome.
Although derived from sampled data for both outcomes
and costs, the ICER is a ratio and, therefore, 95% confidence
intervals cannot be generated using standard statistical
analysis. As described above, non-parametric bootstrapping
was used for the probabilistic sensitivity analysis, to
calculate the 95% confidence intervals for the ICER. Each
of the 1000 bootstrapped ICERs were plotted on a cost-
effectiveness plane (difference in cost versus difference in
effectiveness) [12].
There is no universal agreement on the maximum size an
ICER can be for a decision maker will decide to pay that
amount to achieve a given improvement in effectiveness.
Generation of a cost-effectiveness acceptability curve
(CEAC) provides a measure of the probability that an ICER
will be less than the decision maker’s ceiling willingness to
pay (WTP) [13]. This plots the cumulative probability that a
specified treatment is cost effective (taken from the cost-
effectiveness plane) against a series of putative ceiling
amounts that decision makers would be willing to pay for
the treatment. The higher a decision maker’s willingness to
pay, the higher the probability that the treatment will be
considered cost effective.3. Results
3.1. Patient characteristics and allocation to treatment
courses
Of a total clinic population of 220, 120 patients received
treatment with intravenous antibiotics during the study
period and 116 (97%) were eligible for the study. Four
patients were excluded: refused access to medical records,
shared care, final FEV1 value missing, or clinical records
missing (one patient each). The 116 patients received 454
courses of intravenous antibiotics during the one-year study
period. In 213 of these courses, the intention had been to
treat the patient in hospital and, in the other 214 courses, the
intention had been to treat the patient at home. However, in
practice, 71 (15.6%) of the courses included a mixture of
home and hospital treatment. The mean total length of
courses classified as home treatment was 16 days (range 3–
44 days), with a mean of 14 days at home and 2 days in
hospital. The mean total length of courses classified ashospital treatment was 15 (range 3–172) days, with a mean
of 12 days in hospital and 3 days at home.
A total of 47 patients were allocated to the ‘‘home’’ group,
51 to ‘‘hospital’’ and 18 to ‘‘both’’ for their treatment during
the one-year study period. ‘‘Home’’ patients had a total mean
of 63 (range 10–182) days treatment, with a mean of 52 days
at home and 11 days in hospital. ‘‘Hospital’’ patients had a
mean total of 54 (range 8–308) days of treatment, with means
of 45 days in hospital and 9 days at home. ‘‘Both’’ patients
had a mean total of 66 (14–166) days treatment, with means
of 40 days at home and 26 days in hospital.
There were no differences in patient characteristics or
lung function between the treatment groups at the start of
the one-year study period (Table 2).
3.2. Clinical effectiveness of treatment courses
Spirometry data were missing for 19/454 courses (14
home and 5 hospital). For each course of treatment, the
mean percentage improvement in FEV1 from their baseline
‘‘best’’ was statistically significantly higher for patients
receiving hospital courses than those receiving home
courses (mean difference 4.6%, 95% CI: 1.8 to 7.4,
p =0.001). Overall, 13.6% of courses were classified as
‘‘effective’’. However, statistically significantly more hos-
pital (41 /236, 17.4%) courses were classified as ‘‘effective’’
than home courses (18 /199, 9.0%), p =0.001.
3.3. Clinical effectiveness over one-year study period
All 116 patients were included in the analysis of outcome
after 1 year. There was a mean percentage decline in FEV1,
compared with baseline average, for ‘‘home’’ patients but an
improvement in ‘‘hospital’’ patients (Tukey’s HSD mean
difference 10.1%, 95% CI: 2.9% to 17.2%, p =0.003). The
number of patients in whom treatment was classified as
‘‘effective’’ was higher in the ‘‘hospital’’ group than the
‘‘home’’ group (Table 3). When effective was defined as a
percentage decline in FEV1 of 2% over one year, the
difference was statistically significant ( p =0.045), but not
when defined as a percentage decline of 0%.
3.4. Costs of treatment courses
For the 454 courses, the mean total cost per course of
intravenous antibiotics was U4729 (range U515 to U50,733).
The total cost of administering hospital courses was
statistically significantly higher for hospital compared with
home courses, with a mean difference of U2836 (95% CI
U2151 to U3522, p <0.001, independent samples t-test).
3.5. Costs over study year
For the 116 patients over 1 year, considering the original
sampled data, the cost of hospital accommodation was
statistically significantly higher for ‘‘hospital’’ compared
Table 2
Summary of patient characteristics at start of one-year study (total=116)
‘‘Home’’ (n =47) ‘‘Hospital’’ (n =51) ‘‘Both’’ (n =18)
Mean (range) age: years 26 (17–43) 26 (16–47) 25 (19–42)
Male/female: % 36.2/63.8 58.8/41.2 61.1/38.9
Infecting micro-organism: N (%)
Pseudomonas aeruginosa 43 (91.5) 42 (82.4) 18 (100.0)
Burkholderia cepacia 6 (12.8) 9 (17.6) 3 (16.7)
Other Pseudomonas spp 0 2 (3.9) 0
Staphylococcus aureusa 8 (17.0) 7 (13.7) 2 (11.1)
Other 19 (40.4) 24 (47.1) 8 (44.4)
Concomitant treatment: N (%)
Nebulised rhDNase 30 (63.8) 32 (62.7) 13 (72.2)
Nebulised colistin 26 (55.3) 21 (41.2) 11 (61.1)
Nebulised gentamicin 6 (12.8) 2 (3.9) 1 (5.6)
Nebulised tobramycin 2 (4.3) 0 0
Oral antibiotics 43 (91.5) 45 (88.2) 16 (88.9)
Inhaled/neb corticosteroids 45 (95.7) 48 (94.1) 16 (88.9)
Regular oral corticosteroids 5 (10.6) 5 (9.8) 2 (11.1)
Inhaled/neb bronchodilators 44 (93.6) 51 (100.0) 18 (100.0)
Oral bronchodilators 26 (55.3) 36 (70.6) 11 (61.1)
Lung function: percent predicted FEV1, mean (SD)
‘‘Best’’ 64.7 (22.4) 59.3 (22.1) 60.6 (19.1
‘‘Average’’ 54.8 (19.0) 49.3 (18.6) 50.4 (16.0)
a Including 2 patients with methicillin-resistant Staphylococcus aureus.
Table 3
Effectiveness at end of one-year study period compared with baseline
‘‘average’’ FEV1 values: number of patients (%)
All patients
(n =116)
‘‘Home’’
(n =47)
‘‘Hospital’’
(n =51)
‘‘Both’’
(n =18)
Base case: 0% decline
Effective 59 (50.9%) 20 (42.6%) 30 (58.8%) 9 (50.0%)
2% decline
Effective 62 (53.4%) 20 (42.6%)* 32 (62.7%)* 10 (55.6%)
* p =0.045.
J. Thornton et al. / Journal of Cystic Fibrosis 4 (2005) 239–247 243with ‘‘home’’ patients ( p <0.001, independent samples t-
test) (Table 4). There was no statistically significant differ-
ence in cost for any other resource use in secondary care.
The total cost of treating ‘‘hospital’’ patients was higher than
treating ‘‘home’’ patients. When bootstrap samples were
taken of the total costs of treatment, the mean difference
between total cost of ‘‘home’’ and ‘‘hospital’’ treatment was
U9080, 95% CI U2971 to U15,189, p <0.001.
3.6. Other resources
A total of 81 /116 questionnaires (70%) were returned.
From these, 25 /40 ‘‘home’’, 17 /34 ‘‘hospital’’ and 3 /7
‘‘both’’ patients were in full or part-time work or education
and 65% ‘‘home’’, 93% ‘‘hospital’’ and 67% ‘‘both’’ patients
had to take time off from work or education during treatment.
The length of time taken off work or education during the
most recent infective episode was 0–7 weeks.
For travel to outpatient clinic appointments at the start of
antibiotic treatment, 60% of ‘‘home’’ patients used their own
car, 33% had a lift from family or friends and 7% used
hospital transport. When admitted, 29% used their own car,
53% had a lift from family or friends, 3% used a taxi and 12%
used hospital transport.
Around 60% of patients needed 30–60 min to prepare and
administer each dose of home intravenous antibiotics. A total
of 17 /40 (43%) ‘‘home’’ patients contacted the CF clinic
during their treatment and 3 /40 patients received a home visit
by a CF nurse. Some patients had help with home intravenous
antibiotic treatment from an informal care-giver; this
included either help with preparation, administration andclearing up intravenous antibiotics or involved caring for
children or doing housework while the patient administered
their antibiotics. A total of 22 /40 (54%) ‘‘home’’ patients had
such help; 12 /22 (55%) of these patients were helped by a
parent and 10 /22 (45%) were helped by their partner.
For 20 /22 of ‘‘home’’ patients, the helper lived at the
same address as the patient. 15 /22 ‘‘home’’ patients were
accompanied by their care-giver to outpatient clinic visits at
the start of treatment. For admission to hospital, 22 /24 (92%)
‘‘hospital’’ patients were accompanied and 20/24 (83%)
patients were accompanied at discharge. Some care-givers
took time off work while helping the patient with their
treatment (data missing for 3 patients): 4 /21 care-givers for
‘‘home’’ patients and 3 /22 care-givers for ‘‘hospital’’ patients.
3.7. Economic analysis of treatment courses
Effectiveness data were missing for 19 courses of treat-
ment and, therefore, 435 courses were included in the
Table 4
Costs to health care provider of 1 year of treatment with intravenous antibiotics (data from original sample)
All patients (n =116) ‘‘Home’’ (n =47) ‘‘Hospital’’ (n =51) ‘‘Both’’ (n =18)
Cost of resources per patient, mean (range) /U
iv antibiotics and disposables 8974 (829 to 57,300) 9325 (1122 to 43,833) 7920 (829 to 57,300) 11,044 (2587 to 25,857)
Home kits 25 (0 to 96) 39 (11 to 96) 8 (0 to 64) 33 (11 to 75)
Laboratory testing 101 (0 to 424) 88 (0 to 259) 113 (0 to 424) 103 (4 to 223)
Clinic appointments 546 (0 to 1984) 789 (0 to 1984) 268 (0 to 1357) 702 (0 to 1775)
Hospital stay 8856 (0 to 50,610) 3263 (0 to 20,059)* 14,299 (617 to 50,610)* 8041 (926 to 23,762)
Total cost per patient, mean (range)/£ 18,513 (1537 to 99,828) 13,528 (1537 to 51,898) 22,609 (2873 to 99,828) 19,927 (5,149 to 45,813)
* p <0.001.
Table 5
Summary of ICERs calculated for 1 year of treatment
Effectiveness
(%)
Mean cost per
patient per year
(95% CI) (U)
Bootstrap samples
ICER: mean (2.5 and
97.5 percentiles) (U)
0% decline in FEV1
‘‘Hospital’’ 58.8 22,609 (17,648
to 27,569)
10,923 (221,078,
199,978)
‘‘Both’’ 50.0 19,927 (13,433
to 26,421)
71,710 (434,600,
658,388)
‘‘Home’’ 42.6 13,528 (9989
to 17,068)
2% decline in FEV1
‘‘Hospital’’ 62.7 22,609 (17,648
to 27,569)
12,878 (231,167,
262,204)
‘‘Both’’ 55.6 19,927 (13,433
to 26,421)
39,122 (353,917,
600,602)
‘‘Home’’ 42.6 13,528 (9989
to 17,068)
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missing were subtracted from the total costs of treatment. The
re-calculated mean costs per course were U3223 and U6060,
for home and hospital treatment, respectively. Using the
bootstrapped data, the mean ICER was U42,048 (2.5th and
97.5th percentiles, representing the 95% confidence inter-
vals: U17,300 and U113,478). Thus, U42,048 must be spent to
obtain each additional effective course of treatment in
hospital, compared with at home.
3.8. Economic analysis over study year
The ICERs were calculated based on the level of
effectiveness of treatment (this is the standard method).
Thus, ‘‘hospital’’ (most effective treatment) was compared
with ‘‘both’’ (second most effective), and then ‘‘both’’ was
compared with ‘‘home’’ (least effective) (Table 5). However,
as ‘‘home’’ and ‘‘hospital’’ were the most important treat-
ment groups, an ICER was also calculated for ‘‘hospital’’
compared with ‘‘home’’ for both levels of effectiveness; the
cost-effectiveness planes are displayed in Figs. 1 and 2.
When effective treatment was classed as a 0% decline, the
mean ICER was U46,098 (2.5th and 97.5th percentiles:
374,044 and 362,472). When 2% decline was accept-
able for effective treatment, the mean ICER was U73,885
(2.5th and 97.5th percentiles: U1236 and U269,023). These
are the amounts that must be spent to obtain one more year
of effective treatment with hospital-based care for one
patient. In the cost-effectiveness plane, most data points
were located in the NE plane, indicating increased
effectiveness and increased cost for hospital treatment
compared with home treatment. In Fig. 1, the 2.5th
percentile was just in the NW quadrant, indicating that
there is a slight possibility that hospital treatment may be
less effective and more expensive than home treatment, with
the strictest definition of effectiveness (%). When 2%
decline is still considered effective treatment, this was not
the case. These reflect the results in Table 3.
The CEAC for this intervention is shown in Fig. 3, for
both effectiveness thresholds. From this analysis, we can
say that, if a decision maker is willing to pay up to U262,500
(x axis) for one extra patient with a decline of 2% in FEV1
over 1 year, there is a 95% probability ( y axis) that hospital-
based care will be cost effective. However, if we use adecline of 0% in FEV1 over one year, even if the decision
maker is willing to pay U10 million for one extra patient, the
probability that hospital-based care will be cost effective
never reaches 95%.4. Discussion
This study was the first full cost-effectiveness analysis of
home and hospital treatment in adults with CF. The results
indicate that for both one course and one year of treatment,
where administration of intravenous antibiotics occurs
mostly in hospital, treatment is more effective but more
costly than where administration occurs mostly at home.
The higher cost of hospital treatment results from the cost of
hospital accommodation. Treating patients partly at home
and partly in hospital reduced both cost and effectiveness
compared with full treatment in hospital.
The economic analysis demonstrated that the improved
clinical effectiveness achieved with hospital-based treatment
may only be achieved with the input of considerable extra
resources. Depending on the how effectiveness is defined,
between U46,000 and U73,000 per patient would need to be
spent in order to obtain one more year of effective treatment
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Fig. 1. Cost-effectiveness plane, ‘‘home’’ versus ‘‘hospital’’, decline in FEV1 0% from baseline, with 2.5th and 97.5th percentiles marked as dashed lines.
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When some degree of decline in lung function is permitted
in the definition of clinical effectiveness, results suggest that
a decision maker would have to be willing to pay U262,500
per patient per year for a 95% probability that hospital
treatment will be cost effective. However, for the stricter
definition of effectiveness (that is, no decline in lung
function), it is unlikely that hospital treatment could ever
be cost effective.
We did not attach a monetary value to patient costs
collected through the questionnaire, but it is clear that both
hospital- and home-based treatment incurs costs for patients
and their carers. Whilst hospital-based care leads to costs
incurred because of time off work, home-based care appears
to place more time pressure on informal carers.
A recent review found 11 economic evaluations of home
versus hospital treatment with intravenous antibiotics in-6,000.00
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treatment, whereas this study recruited patients already
receiving usual care at home. Thus, it is more representa-
tive of usual practice. Specific selection of patients for
home-based care leads to improved outcomes in this group
[14]. Bosworth and Nielson selected patients in the same
way as we did and also found that home-based care
produced significantly poorer outcomes [15]. This better
outcome for hospital-treated patients probably results from
a combination of factors. Patients in hospital receive closer
management of their condition from the multidisciplinary
team with intensive physiotherapy, greater dietetic input
and close supervision and monitoring of spirometry and
body weight. Nonetheless, it is not possible to treat all
patients in hospital partly because of insufficient beds and
partly because of the strong preference of many patients for
home treatment.
Potential methods to improve outcome for home-care
patients include careful selection of patients, increased
supervision and support for treatment at home and possibly
the use of specialist commercial home-care companies. These
companies provide a package of care to patients. They deliver
ready-prepared infusions and provide technical support to
patients. In the USA, where home-care companies are more
widely used, many patients also receive nursing support from
these companies.
Better clinical outcomes in hospital may also be a result
of the patients being forced to rest. Our study showed that
home-based patients took less time off work than hospital-
based patients so were not resting. Wolter et al. reported
that patients in hospital reported less fatigue, whereas
home-based patients reported less disruption to family life
and sleep patterns [16]. Thus, patients prefer home treat-
ment for these reasons, although this may be adversely
affecting their recovery.The link between clinical recovery and quality of life
is complex. There is little consensus on how to assess the
long-term effectiveness of respiratory interventions and there
is no standard measure or threshold of effectiveness for use in
treatment of CF. In practice, the main aim of treatment with
intravenous antibiotics is achieving and maintaining the
patient’s best lung function. Most studies report changes in
FEV1, because of ease of measurement. It is not clear what
change in FEV1 should be considered clinically significant
and research suggests that FEV1 is poorly correlated with
patient quality of life [17,18].
There are limitations to this study. There is no accepted
definition of effectiveness of treatment of CF and a measure
had to be developed for use in this study. For single courses of
intravenous antibiotics, it is clinical practice to compare the
FEV1 at the end of the course with the patients’ previous best
values. However, for long-term assessment of outcome it may
be more appropriate to compare changes in lung function
with average values in order to eliminate the effect of
unrepresentative peak values. The ideal outcomewould be no
decline in lung function from baseline. However, a less
stringent definition, allowing some decline, may be more
realistic. Using a definition of effectiveness where some
decline in lung function was permitted increased the number
of patients for whom treatment was considered effective and
showed a significant difference in favour of hospital treat-
ment (Table 3). For the purposes of the economic evaluation,
a dichotomous outcome was needed. When the percentage
change in FEV1 was evaluated as a continuous variable, we
have also shown a significant benefit for hospital treatment
compared with home treatment [7]. Our sample size was
small and it is possible that a bigger sample, particularly in the
‘‘both’’ group, would have demonstrated significant differ-
ences for both definitions of effectiveness. This is reflected in
the wide 2.5th and 97.5th percentiles for the bootstrap ICERs.
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and the results may not be easily transferable to other CF
units.
Although an ideal study would be expected to randomise
patients to home and hospital treatment, a randomised
controlled trial may not be appropriate because it would not
reflect the variation in severity of disease and the number of
antibiotic regimens used for treating respiratory infective
exacerbations and thus would not represent routine practice.
Furthermore, a randomised controlled trial may not be the
best study design for patients with chronic or lifelong
diseases such as CF as they rarely evaluate long-term
outcomes [19].
Finally, this study was not able to examine the effects of
adherence on outcome of treatment. Adherence with treat-
ment in general is recognised as poor in patients with CF [20]
and could be worse in some patients undertaking home
treatment. Patients receive varying levels of home support but
usually rely on family and friends for help in the first instance.
Patients receive visits from the CF specialist nurses on
request but do not receive any other support from the hospital
or community.
In conclusion, this study demonstrated that treatment with
intravenous antibiotics is more effective but also more
expensive in hospital compared with home treatment.
Guidance for researchers and clinical practitioners is required
on how to assess the long-term effectiveness of respiratory
interventions. Treating patients at home reduces the cost to
the health service but shifts costs and responsibility for care to
the patient and their informal care-givers. In the UK, the cost
of using home-care companies is perceived by the hospitals
and health authorities as expensive. However, the impact of
this cost may be different if a wider perspective was taken and
the costs to patients and their care-givers were taken into
account, and improved outcomes could be demonstrated.Acknowledgements
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